Scientists Are Obsessed with THESE TWO Questions

by | Aug 31, 2022 | MYMD

 

Sponsored By


Greetings Traders,

“What causes a person’s body to attack itself?” and “Why is a particular tissue selected as the target?”

Although these questions have completely stumped scientists, what happens to the body has not.  Autoimmune diseases wreak HAVOC on our bodies –  and chances are you or someone you know suffers from one of the over 80 autoimmune diseases! HELP!!!  🆘!

This brings us to a biotech stock we’ve featured lately — MYMD — and the strides it has made with its leading drug candidate, MYMD-1®, in its fight against autoimmune diseases including MS and rheumatoid arthritis.  

So how does MYMD-1® aim to differ from treatments available now?  

That is EXACTLY what MyMD’s short video addresses…

 

 

 

 


 

 

 

 

In case you are like me and want to skip straight to the highlights, the video states, “Most autoimmune diseases are treated by alleviating symptoms rather than addressing the underlying causes.  […] Unlike other TNF-alpha drugs MYMD-1® is designed to stop the underlying causes of chronic inflammatory disease.” 

To reiterate, MYMD-1® is not only being designed to reduce symptoms but to STOP the underlying causes of chronic inflammatory diseases.

Further, the company video overviews its research, pointing to the potential of MYMD-1®, stating, “Overall, these studies suggest that MYMD-1®could be used to regulate the overly active immune responses in patients with auto-immune diseases.”

I want you to watch the FULL video (less than 4 mins long) to understand the life-altering potential of MYMD-1®.

Do yourself a favor and spend some time getting to know more about this revolutionary biotech company.  

MYMD is a $3 stock that has incredible potential.


 

 

 

 

 

 

 

 

62 Calef Hwy #233 Lee, New Hampshire 03861 United States

Questions or concerns about our products? Email Support@360.com  © Copyright 2022, RagingBull – Refund Policy – Privacy Policy – Terms & Conditions

 

 

 

 

*THIS IS AN ISSUER-PAID ADVERTISEMENT, SEE DISCLOSURE BELOW
*ISSUER-PAID ADVERTISEMENT. MyMD, Inc. (“MYMD” or the “Company”) HAS PAID OR
WILL PAY SHERWOOD VENTURES, LLC (“Sherwood”) TWENTY-THOUSAND DOLLARS USD PER MONTH FOR THREE MONTHS (THE “INITIAL TERM”) IN CASH, SHARES OF RESTRICTED COMMON STOCK WITH A VALUE OF ONE-HUNDRED-FIFTY THOUSAND DOLLARS, AND WARRANTS VALUED AT ISSUANCE OF SEVENTY-FIVE THOUSAND DOLLARS FOR MARKETING SERVICES INCLUDING COMMUNICATING TO THE PUBLIC ABOUT THE COMPANY THROUGH SHERWOOD’S AFFILIATE RAGINGBULL.COM, LLC (“RAGING BULL”), AMONG OTHERS. THIS ADVERTISEMENT IS PART OF THOSE ISSUER-PAID MARKETING SERVICES. FOR DETAILED COMPENSATION AND MORE INFORMATION, PLEASE SEE THE FULL DISCLOSURE LOCATED AT HTTPS://BOARDROOMINVESTING.COM/MYMD-DISCLAIMER.

 

 

 

 

DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.

RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.

RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of RagingBull.com, LLC are paid in whole or in part by commission based on their sales of Services to subscribers.

WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.